No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
Buy Rating on KalVista Pharmaceuticals: Sebetralstat Poised to Transform HAE Treatment Landscape
Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating
No Data